Banyai G, Baidi F, Coudreuse D, Szilagyi Z. Cdk1 activity acts as a quantitative platform for coordinating cell cycle progression with periodic transcription. Nat Commun. 2016;7:11161.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Campsteijn C, Ovrebo JI, Karlsen BO, Thompson EM. Expansion of cyclin D and CDK1 paralogs in Oikopleura dioica, a chordate employing diverse cell cycle variants. Mol Biol Evol. 2012;29:487–502.

Article  CAS  PubMed  Google Scholar 

Allan LA, Clarke PR. Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol Cell. 2007;26:301–10.

Article  CAS  PubMed  Google Scholar 

Neganova I, Tilgner K, Buskin A, Paraskevopoulou I, Atkinson SP, Peberdy D, et al. CDK1 plays an important role in the maintenance of pluripotency and genomic stability in human pluripotent stem cells. Cell Death Dis. 2014;5:e1508.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Michowski W, Chick JM, Chu C, Kolodziejczyk A, Wang Y, Suski JM, et al. Cdk1 controls global epigenetic landscape in embryonic stem cells. Mol Cell. 2020;78:459–76.e13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Izadi S, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Mohammadi H, et al. CDK1 in breast cancer: implications for theranostic potential. Anticancer Agents Med Chem. 2020;20:758–67.

Article  CAS  PubMed  Google Scholar 

Xi Q, Huang M, Wang Y, Zhong J, Liu R, Xu G, et al. The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer. Tumour Biol. 2015;36:4939–48.

Article  CAS  PubMed  Google Scholar 

Huang J, Chen P, Liu K, Liu J, Zhou B, Wu R, et al. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Gut. 2021;70:890–9.

Article  CAS  PubMed  Google Scholar 

Chen X, Zhang FH, Chen QE, Wang YY, Wang YL, He JC, et al. The clinical significance of CDK1 expression in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2015;20:e7–12.

Article  PubMed  Google Scholar 

Huang Z, Shen G, Gao J. CDK1 promotes the stemness of lung cancer cells through interacting with Sox2. Clin Transl Oncol. 2021;23:1743–51.

Article  CAS  PubMed  Google Scholar 

Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, KrishnanKutty LN, Osborne DG, et al. CDK1 interacts with Sox2 and promotes tumor initiation in human melanoma. Cancer Res. 2018;78:6561–74.

Article  PubMed  Google Scholar 

Nagy A, Munkacsy G, Gyorffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep. 2021;11:6047.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim SJ, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, Matsushima T, et al. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol. 2008;19:68–72.

Article  CAS  PubMed  Google Scholar 

Xia Q, Cai Y, Peng R, Wu G, Shi Y, Jiang W. The CDK1 inhibitor RO3306 improves the response of BRCA-pro fi cient breast cancer cells to PARP inhibition. Int J Oncol. 2014;44:735–44.

Article  CAS  PubMed  Google Scholar 

Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci USA. 2006;103:10660–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17:93–115.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007;448:811–5.

Article  CAS  PubMed  Google Scholar 

Aleem E, Kiyokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol. 2005;7:831–6.

Article  CAS  PubMed  Google Scholar 

Welch PJ, Wang JY. Coordinated synthesis and degradation of cdc2 in the mammalian cell cycle. Proc Natl Acad Sci USA. 1992;89:3093–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoon CH, Miah MA, Kim KP, Bae YS. New Cdc2 Tyr 4 phosphorylation by dsRNA-activated protein kinase triggers Cdc2 polyubiquitination and G2 arrest under genotoxic stresses. EMBO Rep. 2010;11:393–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herrero-Ruiz J, Mora-Santos M, Giraldez S, Saez C, Japon MA, Tortolero M, et al. betaTrCP controls the lysosome-mediated degradation of CDK1, whose accumulation correlates with tumor malignancy. Oncotarget. 2014;5:7563–74.

Article  PubMed  PubMed Central  Google Scholar 

Bu H, Lan X, Cheng H, Pei C, Ouyang M, Chen Y, et al. Development of an interfering peptide M1-20 with potent anti-cancer effects by targeting FOXM1. Cell Death Dis. 2023;14:533.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Major ML, Lepe R, Costa RH. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol Cell Biol. 2004;24:2649–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raveh B, London N, Schueler-Furman O. Sub-angstrom modeling of complexes between flexible peptides and globular proteins. Proteins-Struct Funct Bioinforma. 2010;78:2029–40.

Article  CAS  Google Scholar 

Barlow KA, Ó Conchúir S, Thompson S, Suresh P, Lucas JE, Heinonen M, et al. Flex ddG: Rosetta ensemble-based estimation of changes in protein-protein binding affinity upon mutation. J Phys Chem B. 2018;122:5389–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Z, Bu H, Yu J, Chen Y, Pei C, Yu L, et al. The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3. Theranostics. 2019;9:2882–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12:954–61.

CAS  PubMed  PubMed Central  Google Scholar 

Stranges PB, Kuhlman B. A comparison of successful and failed protein interface designs highlights the challenges of designing buried hydrogen bonds. Protein Sci. 2013;22:74–82.

Article  CAS  PubMed  Google Scholar 

Shi Z, Tian L, Qiang T, Li J, Xing Y, Ren X, et al. From structure modification to drug launch: a systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy. J Med Chem. 2022;65:6390–418.

Article  CAS  PubMed  Google Scholar 

Schneider-Poetsch T, Ju JH, Eyler DE, Dang YJ, Bhat S, Merrick WC, et al. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat Chem Biol. 2010;6:209–17.

Article